1 / 10

Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre , double - blind , placebo- controlled , randomised trial . Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators

bliss
Download Presentation

Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacyand safety of colchicine for treatment of multiple recurrencesof pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomisedtrial Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators CardiologyDpt. Maria Vittoria Hospital, ASLTO2, Torino, Italy Conflict of interest: None

  2. Background Clinical trials haveshownthatlow-dose colchicine (0·5–1·0 mg daily) isefficacious and safe for treatment and prevention of acute pericarditis and first recurrences. ICAP trial CORP trial RRR 0.56 NNT=3 RRR 0.56 NNT= 4 Ann Intern Med 2011; 155: 409–14 N Engl J Med 2013; 369: 1522–28

  3. CORP-2: Aim To assess the efficacy and safety of colchicine to treatpatients with multiple recurrences of pericarditis(≥2). COlchicine for RecurrentPericarditis-2 J CardiovascMed (Hagerstown) 2007; 8: 830–34

  4. (0·5 mg twicedaily for 6 months for patients>70 kg or 0·5 mg once daily for patients≤ 70 kg) in addition to conventional anti-inflammatory treatment with aspirin, ibuprofen, or indometacin.

  5. Trial profile Lancet 2014; publishedtoday

  6. Outcomes Lancet 2014; publishedtoday

  7. Recurrence-free Survival RR 0.49 NNT= 5 Lancet 2014; publishedtoday

  8. Safety: side effects Lancet 2014; publishedtoday

  9. Updatedsystematicreview on colchicine for pericarditisprevention JCardiovascMed 2014; in press

  10. Conclusions • Colchicine added to conventional anti-inflammatory treatment significantlyreduced the rate of subsequentrecurrences of pericarditis in patients with multiple recurrences. • Takentogether with results from otherrandomisedcontrolled trials, thesefindingssuggestthat colchicine should be probablyregardedas a first-line treatment for either acute or recurrentpericarditis in the absence of contrandications.

More Related